References
1. Hartholt KA, van Beeck EF, Polinder S, et al. Societal consequences of falls in the older population: injuries, healthcare costs, and long-term reduced quality of life. The Journal of trauma . Sep 2011;71(3):748-53. doi:10.1097/TA.0b013e3181f6f5e5
2. falls CfDCaPHaRSIfa.http://www.cdc.gov/homeandrecreationalsafety/falls/adultfalls.html . Accessed October 16, 2020.
3. Seppala LJ, van der Velde N, Masud T, et al. EuGMS Task and Finish group on Fall-Risk-Increasing Drugs (FRIDs): Position on Knowledge Dissemination, Management, and Future Research. Drugs Aging . Apr 2019;36(4):299-307. doi:10.1007/s40266-018-0622-7
4. Seppala LJ, Wermelink A, de Vries M, et al. Fall-Risk-Increasing Drugs: A Systematic Review and Meta-Analysis: II. Psychotropics.Journal of the American Medical Directors Association . Apr 2018;19(4):371.e11-371.e17. doi:10.1016/j.jamda.2017.12.098
5. Seppala LJ, Petrovic M, Ryg J, et al. STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age and ageing . Dec 22 2020;doi:10.1093/ageing/afaa249
6. Iaboni A, Flint AJ. The complex interplay of depression and falls in older adults: a clinical review. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry . May 2013;21(5):484-92. doi:10.1016/j.jagp.2013.01.008
7. van Poelgeest EP, Pronk AC, Rhebergen D, van der Velde N. Depression, antidepressants and fall risk: therapeutic dilemmas-a clinical review.Eur Geriatr Med . Jun 2021;12(3):585-596. doi:10.1007/s41999-021-00475-7
8. Chen Y, Zhu LL, Zhou Q. Effects of drug pharmacokinetic/pharmacodynamic properties, characteristics of medication use, and relevant pharmacological interventions on fall risk in elderly patients. Ther Clin Risk Manag . 2014;10:437-48. doi:10.2147/tcrm.S63756
9. Coupland CA, Dhiman P, Barton G, et al. A study of the safety and harms of antidepressant drugs for older people: a cohort study using a large primary care database. Health Technol Assess . Aug 2011;15(28):1-202, iii-iv. doi:10.3310/hta15280
10. Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol . Oct 2005;45(10):1106-22. doi:10.1177/0091270005280297
11. Sultana J, Spina E, Trifirò G. Antidepressant use in the elderly: the role of pharmacodynamics and pharmacokinetics in drug safety.Expert opinion on drug metabolism & toxicology . Jun 2015;11(6):883-92. doi:10.1517/17425255.2015.1021684
12. Spina E, Scordo MG. Clinically significant drug interactions with antidepressants in the elderly. Drugs & aging . 2002;19(4):299-320. doi:10.2165/00002512-200219040-00004
13. Hiemke C, Bergemann N, Clement HW, et al. Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017.Pharmacopsychiatry . Jan 2018;51(1-02):9-62. doi:10.1055/s-0043-116492
14. van Wijngaarden JP, Dhonukshe-Rutten RA, van Schoor NM, et al. Rationale and design of the B-PROOF study, a randomized controlled trial on the effect of supplemental intake of vitamin B12 and folic acid on fracture incidence. BMC geriatrics . Dec 2 2011;11:80. doi:10.1186/1471-2318-11-80
15. Swart KM, Ham AC, van Wijngaarden JP, et al. A Randomized Controlled Trial to Examine the Effect of 2-Year Vitamin B12 and Folic Acid Supplementation on Physical Performance, Strength, and Falling: Additional Findings from the B-PROOF Study. Calcified tissue international . Jan 2016;98(1):18-27. doi:10.1007/s00223-015-0059-5
16. ATC and DDD index. WHO Collaborating Centre for Drug Statistics Methodology, Oslo . https://www.whocc.no/atc_ddd_index/ .
17. The prevention of falls in later life. A report of the Kellogg International Work Group on the Prevention of Falls by the Elderly.Danish medical bulletin . Apr 1987;34 Suppl 4:1-24.
18. Gnjidic D, Hilmer SN, Blyth FM, et al. Polypharmacy cutoff and outcomes: five or more medicines were used to identify community-dwelling older men at risk of different adverse outcomes.J Clin Epidemiol . Sep 2012;65(9):989-95. doi:10.1016/j.jclinepi.2012.02.018
19. Debonnel G, Saint-Andre E, Hebert C, de Montigny C, Lavoie N, Blier P. Differential physiological effects of a low dose and high doses of venlafaxine in major depression. Int J Neuropsychopharmacol . Feb 2007;10(1):51-61. doi:10.1017/S1461145705006413
20. Bujang MA, Sa’at N, Sidik T, Joo LC. Sample Size Guidelines for Logistic Regression from Observational Studies with Large Population: Emphasis on the Accuracy Between Statistics and Parameters Based on Real Life Clinical Data. Malays J Med Sci . Jul 2018;25(4):122-130. doi:10.21315/mjms2018.25.4.12
21. Hartholt KA, Becker ML, van der Cammen TJ. Drug-induced falls in older persons: is there a role for therapeutic drug monitoring?Ther Adv Drug Saf . Apr 2016;7(2):39-42. doi:10.1177/2042098615627806
22. Rodriguez de la Torre B, Dreher J, Malevany I, et al. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit . Aug 2001;23(4):435-40. doi:10.1097/00007691-200108000-00019
23. Mol A, Bui Hoang PTS, Sharmin S, et al. Orthostatic Hypotension and Falls in Older Adults: A Systematic Review and Meta-analysis.Journal of the American Medical Directors Association . May 2019;20(5):589-597.e5. doi:10.1016/j.jamda.2018.11.003
24. Chew ML, Mulsant BH, Pollock BG, et al. Anticholinergic activity of 107 medications commonly used by older adults. Journal of the American Geriatrics Society . Jul 2008;56(7):1333-41. doi:10.1111/j.1532-5415.2008.01737.x
25. Drenth-van Maanen AC, Wilting I, Jansen PAF. Prescribing medicines to older people-How to consider the impact of ageing on human organ and body functions. Br J Clin Pharmacol . Oct 2020;86(10):1921-1930. doi:10.1111/bcp.14094
26. Eap CB, Gründer G, Baumann P, et al. Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests): focus on antidepressants.World J Biol Psychiatry . May 12 2021:1-68. doi:10.1080/15622975.2021.1878427
27. Asberg M, Cronholm B, Sjöqvist F, Tuck D. Correlation of subjective side effects with plasma concentrations of nortriptyline. Br Med J . Oct 3 1970;4(5726):18-21. doi:10.1136/bmj.4.5726.18
28. Asberg M, Crönholm B, Sjöqvist F, Tuck D. Relationship between plasma level and therapeutic effect of nortriptyline. Br Med J . Aug 7 1971;3(5770):331-4. doi:10.1136/bmj.3.5770.331
29. Ostad Haji E, Hiemke C, Pfuhlmann B. Therapeutic drug monitoring for antidepressant drug treatment. Curr Pharm Des . 2012;18(36):5818-27. doi:10.2174/138161212803523699
30. Hermann M, Waade RB, Molden E. Therapeutic Drug Monitoring of Selective Serotonin Reuptake Inhibitors in Elderly Patients. Ther Drug Monit . Aug 2015;37(4):546-9. doi:10.1097/ftd.0000000000000169
31. Wyska E. Pharmacokinetic considerations for current state-of-the-art antidepressants. Expert opinion on drug metabolism & toxicology . Oct 2019;15(10):831-847. doi:10.1080/17425255.2019.1669560
32. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry.Pharmacopsychiatry . Nov 2004;37(6):243-65. doi:10.1055/s-2004-832687
33. Waade RB, Molden E, Refsum H, Hermann M. Serum concentrations of antidepressants in the elderly. Ther Drug Monit . Feb 2012;34(1):25-30. doi:10.1097/FTD.0b013e318241dce0
34. Tveit K, Hermann M, Waade RB, Nilsen RM, Wallerstedt SM, Molden E. Use of Antidepressants in Older People during a 10-Year Period: An Observational Study on Prescribed Doses and Serum Levels. Drugs & aging . Sep 2020;37(9):691-701. doi:10.1007/s40266-020-00784-9
35. Lundmark J, Bengtsson F, Nordin C, Reis M, Wålinder J. Therapeutic drug monitoring of selective serotonin reuptake inhibitors influences clinical dosing strategies and reduces drug costs in depressed elderly patients. Acta psychiatrica Scandinavica . May 2000;101(5):354-9. doi:10.1034/j.1600-0447.2000.101005354.x
36. Ostad Haji E, Tadić A, Wagner S, et al. Association between citalopram serum levels and clinical improvement of patients with major depression. Journal of clinical psychopharmacology . Jun 2011;31(3):281-6. doi:10.1097/JCP.0b013e318218f503
37. Lamb SE, Jørstad-Stein EC, Hauer K, Becker C. Development of a common outcome data set for fall injury prevention trials: the Prevention of Falls Network Europe consensus. Journal of the American Geriatrics Society . Sep 2005;53(9):1618-22. doi:10.1111/j.1532-5415.2005.53455.x